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Abstract
Background & Aims
Narrative reviews of paediatric NAFLD quote prevalences in the general population that
range from 9% to 37%; however, no systematic review of the prevalence of NAFLD in chil-
dren/adolescents has been conducted. We aimed to estimate prevalence of non-alcoholic
fatty liver disease (NAFLD) in young people and to determine whether this varies by BMI
category, gender, age, diagnostic method, geographical region and study sample size.
Methods
We conducted a systematic review and meta-analysis of all studies reporting a prevalence
of NAFLD based on any diagnostic method in participants 1–19 years old, regardless of
whether assessing NAFLD prevalence was the main aim of the study.
Results
The pooled mean prevalence of NAFLD in children from general population studies was
7.6% (95%CI: 5.5% to 10.3%) and 34.2% (95% CI: 27.8% to 41.2%) in studies based on
child obesity clinics. In both populations there was marked heterogeneity between studies
(I2 = 98%). There was evidence that prevalence was generally higher in males compared
with females and increased incrementally with greater BMI. There was evidence for differ-
ences between regions in clinical population studies, with estimated prevalence being high-
est in Asia. There was no evidence that prevalence changed over time. Prevalence
estimates in studies of children/adolescents attending obesity clinics and in obese children/
adolescents from the general population were substantially lower when elevated alanine
aminotransferase (ALT) was used to assess NAFLD compared with biopsies, ultrasound
scan (USS) or magnetic resonance imaging (MRI).
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Conclusions
Our review suggests the prevalence of NAFLD in young people is high, particularly in those
who are obese and in males.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined as the accumulation of fat in the liver in
the absence of excessive alcohol consumption or other known liver pathologies.[1] It is a spec-
trum of disease ranging from steatosis (fat infiltration into the liver) to steatohepatitis, which is
characterised by hepatocellular inflammation and injury, to fibrosis and eventually cirrhosis.
[2,3] NAFLD is now recognised as one of the most common causes of chronic liver disease in
young people in the developed world.[4,5]
The prevalence of NAFLD in adults and children in the general population is uncertain and
difficult to assess accurately due to a lack of simple, non-invasive diagnostic tests.[6] The ‘gold
standard’ for diagnosing NAFLD and its severity is a liver biopsy, but this is neither feasible
nor ethical to use in healthy populations. Even in clinical practice, liver biopsies are used for
clarity of chronic hepatitis (for example, in patients with indeterminate or discordant results
unable to exclude advanced fibrosis).[7] Consequently, population prevalence is usually esti-
mated by serum biomarkers of NAFLD and/or evidence of fatty liver on USS or magnetic reso-
nance imaging (MRI).
The commonest serum biomarkers used to assess NAFLD prevalence in research settings
and to identify patients who may benefit from further investigation in clinical settings are ala-
nine aminotransferase (ALT) and aspartate aminotransferase (AST).[8] There is currently no
consensus on the thresholds of liver enzymes that should be used to indicate NAFLD or
whether thresholds should be specific to sex, age and/or ethnicity.[9–15] Both liver enzymes
have been reported to correlate with the degree of liver fat infiltration, inflammation [16–20],
in adults and children, though not consistently with fibrosis[5]. However, estimated sensitivity
and specificity of these serum indicators for identifying NAFLD remains low compared with
histology and imagining techniques.[5] One study of obese children estimated sensitivity and
specificity for the prediction of NAFLD with ALT>30U/L to be 64% and 81%, respectively
and with ALT>40U/L to be 41% and 89%, respectively compared to a hepatic fat fraction
>9% on MRI.[15] USS is the most commonly used imaging modality for determining NAFLD
prevalence in the general population as it is relatively inexpensive and, when compared to liver
biopsy, has good estimated sensitivity (85%) and specificity (94%) for diagnosing moderate to
severe steatosis.[21] It is less reliable for detecting mild steatosis.[22] Compared with liver
biopsy, MRI has high estimated sensitivity and specificity for diagnosing steatosis across the
whole spectrum of disease (sensitivity and specificity ranges for detecting mild to severe steato-
sis: 82–97% and 76–95%, respectively). However, MRI is expensive and therefore not often
used in general population studies.[22]
Whilst narrative reviews of paediatric NAFLD quote prevalence estimates in the general
population that range from 9 to 37%,[2,23] to date, no systematic review of the prevalence of
NAFLD in children/adolescents has been conducted. Therefore, the true prevalence of the dis-
ease and how this varies over time and with age, gender, geographical region, obesity status
and assessment method is unknown. Here we report results of a systematic review and meta-
analysis of studies reporting the prevalence of NAFLD in children and adolescents aged
between 1 and 19 years, in the general population and in populations of clinically obese
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adolescents. We aimed to estimate the prevalence of NAFLD in young people and to determine
whether and how this varies over time, by body mass index (BMI) category, gender, age, diag-
nostic method, geographical region and study sample size.
Methods
Study eligibility and identification
Studies were eligible for the review if they measured prevalence of NAFLD based on any diag-
nostic method (i.e. biopsy, USS, MRI or other scans or liver enzymes) in participants aged
between 1 and 19 years. Studies using blood-based biomarkers to estimate prevalence were eli-
gible irrespective of the liver enzyme and threshold that was used to define NAFLD. Studies of
participants with previous or existing liver disease, for example, if the sample were a group of
children that had been selected for further analysis because of hepatomegaly or elevated trans-
aminases, were not eligible because we were unable to obtain a prevalence estimate for them
(i.e. because all participants had some evidence of liver disease, we had no denominator with
which to estimate prevalence). Diagnosis of NAFLD did not require studies to have excluded
alcohol-related fatty liver disease.
A systematic search was conducted in PubMed (US National Library of Medicine, National
Institutes of Health) to identify all potentially relevant publications up to October 2013. Our
search strategy had two components, the first including terms related to NAFLD and the sec-
ond including terms that would identify studies specifically in children or adolescents. Search
terms entered into PubMed are detailed in S1 File. The search was restricted to humans. Refer-
ence lists of all papers identified as relevant were checked for further relevant studies.
Study and data selection
One author (EA) reviewed all titles retrieved by the search, excluded clearly irrelevant publica-
tions and screened all remaining abstracts for eligibility. Full text papers of those potentially eli-
gible were obtained for further evaluation. Papers were discarded if they did not present
original data (if two studies published on the same cohort, the largest study was considered).
We excluded studies when the publications were inaccessible from any British library or we
were unable to obtain translations into English. General population studies were excluded if
they did not use random samples (for example, studies where obese cases and lean controls
were selected from a general population were excluded) so as not to over- or under-represent a
particular BMI category.
Data extraction
Following the identification of all potentially relevant papers, data were extracted by EA and
one of DAL, LDH or AF, so that two investigators reviewed each paper independently using a
standardised extraction form. Any discrepancies in the extractions were discussed and an
agreement was made by consensus. Data from non-English language papers were extracted by
colleagues who were fluent in the relevant language. One publication in Japanese that could
not be translated was excluded from this review (Fig 1). Where possible, the prevalence of
NAFLD was extracted for the overall study sample (with males and females combined) and
separately by gender. In general population studies we also extracted NAFLD prevalence by
BMI category (i.e. normal weight, overweight and obese) where possible. For intervention stud-
ies the pre-intervention prevalence was recorded. In some studies the prevalence of NAFLD
was not reported directly but could be calculated from published tables and figures. Study
authors were contacted for additional data or clarification when required.
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Meta-analytical methods for estimating the prevalence of NAFLD
All analyses were conducted in Stata MP Version 13.1. Meta-analyses were conducted to exam-
ine prevalence in the general population and for clinical obese populations of children/adoles-
cents. Several studies of clinical obese populations used more than one diagnostic method to
estimate the prevalence of NAFLD (for example, some studies reported two separate NAFLD
prevalence estimates by USS and by elevated ALT). We randomly selected one of the methods
to include in analyses and conducted a sensitivity analysis to check whether the overall preva-
lence in clinical obese population studies differed when alternative diagnostic methods were
used.
As NAFLD is strongly associated with obesity,[24,25] we decided a priori to analyse studies
with random samples from the general population separately from those conducted in clinical
obese populations (i.e. where participants were recruited through their attendance at a primary
or secondary care obesity service). Children seen by a physician because of their obesity are
likely to be different from those children (even with the same BMI) in the general population
who have not been referred to a clinical obesity team.
The logit transformation was applied to prevalence proportions to better approximate a
normal distribution, and pooled logit prevalence estimates were back transformed to their orig-
inal scale for ease of interpretation. As a sensitivity analysis we also assessed results when an
arcsine transformation was used instead of a logit transformation.[26,27] A random-effects
model was used to estimate the average prevalence across studies, with 95% confidence limits.
Heterogeneity was quantified using estimates of I2, which is the percentage of the total
observed variability that is due to true prevalence differences between studies rather than
chance variation.[28] We also present 95% prediction intervals, which portray the extent of
heterogeneity by providing the range in which we would expect the prevalence of NAFLD to lie
in a new study, 95% of the time.[29]
Fig 1. Study Selection.
doi:10.1371/journal.pone.0140908.g001
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Assessing differences in NAFLD prevalence by BMI, gender, age,
publication year, diagnostic method, geographical region and study
sample size
A subset of studies reported prevalence estimates stratified by gender or by BMI category. We
performed meta-analyses for each of these subgroups separately to provide estimates of preva-
lence for each gender or BMI category. In addition, to formally assess whether there was evi-
dence of a difference in prevalence by gender or BMI, we compared NAFLD prevalence within
studies: (i) in males compared with females and (ii) per increase in BMI category (i.e. assuming
a linear association between BMI category and log-odds of NAFLD). We then pooled these
within-study estimates (differences in logit prevalences or, equivalently, log odds ratios) using
random effects meta-analysis, producing summary odds ratios. Since the assumption of linear-
ity may be questionable, we also obtained the pooled NAFLD odds ratio for obese participants
compared with normal and overweight (combined) and for obese and overweight (combined)
participants compared with normal weight participants. This allowed us to check that any esti-
mated association was robust to the linearity assumption.
Univariable meta-regression was used to assess whether the following study-level character-
istics were associated with NAFLD prevalence in either general or clinical population studies:
diagnostic method (categorised as ALT, USS or MRI), average age of participants (categorised
as 015 and>15 years), publication year (before 2005, 2005 to 2010 and after 2010), geo-
graphical region of study (categorised as Europe, Asia, Middle East and North Africa, North
America, South America and Oceania), and sample size (categorised as above or below the
median sample size: n = 321 for general population studies and n = 77 for clinical studies). Esti-
mates of the average prevalence with 95% CIs in each subgroup were calculated from meta-
regression coefficients. P values for differences between subgroups are also reported. In addi-
tion to examining the association between publication year and prevalence using univariable
meta-regression analyses, we also performed sensitivity analyses in which only those studies
published within the last five years were included.
Results
The search retrieved 1767 publications of which 74 are included in this systematic review, cor-
responding to 76 independent study populations, as there were two studies which presented
prevalence estimates from surveys of two different study samples at different points in time
(Fig 1). A full description of included studies is provided in Tables A (general population stud-
ies) and B (clinical population studies) in S1 File. Full references for each study are also pro-
vided in S1 File. Sample sizes ranged from 7 to 6,895; median n = 87. The oldest study was
published in 1995. The main aim of the majority of studies was to examine associations of
NAFLD with potential risk factors and/or outcomes. Overall, 18 studies (20 independent study
populations) were conducted in general populations and 56 studies in clinical populations of
obese children/adolescents (56 independent study populations). Although the prevalence esti-
mates extracted for this systematic review were reported by studies of various designs (e.g.
cross sectional, prospective and intervention studies), prevalence estimates themselves are, by
nature, cross-sectional.
The most commonly used diagnostic method in general population studies was USS
(n = 10/18, 56% of studies), followed by elevated ALT (n = 8/18, 44% of studies). One study
used more than one method and reported prevalence estimates from each. Only one general
population study had biopsy data from autopsies and no studies used MRI or computed
tomography. In studies of clinical populations of obese children/adolescents, USS was the most
common method for assessing NAFLD (n = 41/56, 73%), followed by elevated ALT (n = 19/56,
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34%) and MRI (n = 9/56, 16%). Fourteen studies used more than one method and reported
prevalence estimates from each. One study of obese clinical populations had biopsy data. The
most common ALT threshold used to diagnose NAFLD in both types of study was 40 U/l (5 of
9 general population studies and 7 of 19 clinical studies used this threshold).
There was considerable heterogeneity among both the general population studies and the
clinical obese population studies (I2 = 98% in both cases). The overall mean prevalence of
NAFLD in general population studies was 7.6% (95%CI: 5.5% to 10.3%, N studies = 20, Fig 2).
The 95% prediction interval ranged from 1.6% to 29.3%, reflecting the between-study heteroge-
neity. Prevalence was notably higher in studies of clinical obese populations (average across
studies = 34.2%, 95%CI: 27.8% to 41.2%, N studies = 56, 95% prediction interval 5.2% to
83.1%, Fig 3).
Differences in NAFLD prevalence by BMI, gender, age, publication year,
diagnostic method, geographical region and study sample size
NAFLD prevalence by BMI in general population studies. Nine general population stud-
ies reported NAFLD prevalence estimates by BMI category. Meta-analysis results for each cate-
gory separately (Table 1) indicate that, across studies, prevalence of NAFLD increased
considerably on average with increasing BMI category. Interestingly, when stratified by diag-
nostic method and BMI category (Table C in S1 File), the pooled prevalence estimate from
studies using USS was lower than that from studies using ALT in the normal weight group;
whilst in the obese group the prevalence estimate was higher in studies using USS. The meta-
analysis of within-study estimates of change in NAFLD prevalence per increase in BMI cate-
gory yielded an odds ratio of 5.48 (95% CI: 3.33 to 8.99, I2 = 78%), which agrees with the
between-study analysis (i.e. both indicate higher prevalence with higher BMI). The odds ratio
for NAFLD in overweight and obese participants compared with normal weight participants
was 13.36 (95% CI: 9.09 to 18.02, I2 = 77%) and for obese compared with normal weight and
overweight participants it was 13.74 (95% CI: 9.92 to 19.03, I2 = 88%).
Fig 2. Estimates of the prevalence of NAFLD in children from general population studies.Overall mean
estimate and prediction intervals are calculated from a random effects meta-analysis.
doi:10.1371/journal.pone.0140908.g002
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Fig 3. Estimates of the prevalence of NAFLD in children from clinical obese population studies.Overall mean estimate and prediction intervals are
calculated from a random effects meta-analysis.
doi:10.1371/journal.pone.0140908.g003
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NAFLD prevalence by gender. 15 general and 27 clinical obese population studies
reported NAFLD prevalence stratified by gender. Meta-analysis of these gender-specific results
(Table 1) shows that prevalence estimates were higher on average in males than females in both
general population and clinical studies, although confidence intervals overlapped. Interestingly,
when stratified by both diagnostic method and gender (Table D in S1 File), prevalence estimates
in general population studies were similar in males and females in studies using USS, but higher
in males in studies using ALT to assess NAFLD. In clinical population studies, pooled estimates
were consistently higher in males, regardless of the diagnostic method used. Meta-analysis of
within-study comparisons of NAFLD prevalence in males versus females in general population
and clinical studies provided statistical evidence that males have higher prevalence of NAFLD
than females, although with considerable heterogeneity across studies (pooled OR of males ver-
sus females in general population studies = 1.63, 95% CI: 1.10 to 2.41, I2 = 89%, Fig 4 and
pooled OR in clinical obese studies = 2.02, 95%CI: 1.59 to 2.58, I2 = 73%, Fig 5).
NAFLD prevalence by diagnostic method. In general population studies, there was no
statistical evidence from the meta-regression that NAFLD prevalence differed by diagnostic
method (Table 2). In clinical studies of obese populations, there was strong statistical evidence
that prevalence differed by diagnostic method. Studies using ALT had a lower mean prevalence
estimate than studies using USS or MRI and in the study using biopsies prevalence was higher
(Table 2).
NAFLD prevalence by age. In both general and clinical obese population studies, there
was no evidence from the meta-regression that prevalence differed in studies with an average
age over 15 years compared with studies with an average age below or equal to 15 years
(Table 2).
NAFLD prevalence by publication year. In both general and clinical obese population
studies, there was no evidence from the meta-regression that prevalence differed by publication
year (Table 2). The sensitivity analyses in which only studies published within the last 5 years
were included in the meta-analysis provided pooled prevalence estimates of 7.1% (95% CI:
4.3% to 11.7%, N studies = 9) for general population studies and 31.8% (95% CI: 23.0% to
42.1%, N studies = 25) for clinical obese populations studies. These estimates are similar to the
pooled prevalence estimates from the main analyses.
NAFLD prevalence by geographical region. In general population studies, there was no
evidence from the meta-regression that prevalence differed by geographical region (Table 2).
Table 1. NAFLD prevalence in studies reporting estimates separately for males and females, and (in
general population studies only) separately for normal weight, overweight and obese subgroups.
Prevalence (%) and 95% CI*
General population studies Clinical obese population studies
Male 9.0 (6.5 to 12.5) (n = 15, I2 = 94.4,
Tau2 = 0.45)
35.3 (26.0 to 45.8) (n = 27, I2 = 97.5,
Tau2 = 1.24)
Female 6.3 (3.8 to 10.4) (n = 15, I2 = 96.5,
Tau2 = 1.04)
21.8 (15.5 to 29.8) (n = 27, I2 = 95.7,
Tau2 = 1.09)
Normal
weight
2.3 (1.5 to 3.6) (n = 9, I2 = 68.9, Tau2 =
0.27)
-
Overweight 12.5 (9.2 to 16.7) (n = 9, I2 = 63.7, Tau2 =
0.12)
-
Obese 36.1 (24.6 to 49.4) (n = 9, I2 = 92.2, Tau2 =
0.60)
-
*Combines all diagnostic methods
doi:10.1371/journal.pone.0140908.t001
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In clinical studies of obese populations, there was evidence that the prevalence differed by geo-
graphical region; prevalence estimates being lower in studies from South America and higher
in the studies from Asia, than studies from Europe, Middle East/North Africa and North
America (Table 2).
NAFLD prevalence by study sample size. In general population studies the meta-regres-
sion provided some evidence that prevalence was higher on average in studies with smaller
sample sizes (Table 2). There was no evidence that the study sample size was associated with
prevalence in clinical studies of obese populations (Table 2).
Fig 4. Meta-analysis of within-study comparisons of NAFLD prevalence in males versus females in
general population studies.
doi:10.1371/journal.pone.0140908.g004
Fig 5. Meta-analysis of within-study comparisons of NAFLD prevalence in males versus females in
clinical population studies.
doi:10.1371/journal.pone.0140908.g005
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Sensitivity analyses
For the obese clinical population studies using more than one method to estimate the preva-
lence of NAFLD, we randomly selected one of the methods in each study to include in analyses.
Overall prevalence estimates were very similar when the alternative diagnostic method was
used (33.4%, 95% CI: 27.3 to 40.2, I2 = 98%). Overall prevalence estimates were also similar
when an arcsine transformation was used instead of logit for general population studies (8.6%,
95% CI: 6.3 to 11.3, I2 = 98%) and for clinical obese population studies (35.6%, 95% CI: 29.6 to
41.7, I2 = 98%).
Discussion
Our systematic review, which extensively searched published evidence for all studies reporting
prevalence of NAFLD in children and adolescents aged between 1 and 19 years, irrespective of
whether prevalence estimate was the main aim of the study or not, has demonstrated higher
NAFLD prevalences in studies in clinical obese populations (mean prevalence 34.2%) than in
general population studies (7.6%). The substantial heterogeneity between studies means that
the predicted range of NAFLD prevalence is wide in both clinically obese and general
Table 2. Univariable regressions of study-level predictors of NAFLD prevalence in general and clinical obese population studies.
General population studies Clinical population studies
N
studies
Prevalence (95%
CI)
P for
difference
Residual
I2
N
studies
Prevalence (95%
CI)
P for
difference
Residual
I2
Diagnostic method Total: 20 Total: 56
USS 10 7.6 (3.8 to 14.3) 0.83 97% 34 41.3 (34.6 to 48.3) <0.01 93%
MRI - - 7 36.5 (18.0 to 60.1)
ALT 9 7.0 (1.3 to 30.4) 14 13.7 (6.2 to 27.6)
Biopsy 1 13.1 (0.7 to 76.4) 1 82.9 (36.4 to 97.6)
Age Total: 17 Total: 46
>5 and 15 6 11.0 (5.5 to 20.8) 0.24 97% 25 27.5 (19.8 to 36.8) 0.27 97%
>15 9 6.4 (1.1 to 29.1) 21 36.8 (16.9 to 62.5)
Publication year Total: 20 Total: 56
Before 2005 4 10.6 (3.7 to 26.6) 0.72 98% 8 30.4 (18.1 to 46.4) 0.34 98%
2005–2010 10 6.6 (0.6 to 44.9) 30 39.1 (11.8 to 70.9)
After 2010 6 7.4 (0.6 to 51.2) 18 39.8 (7.7 to 63.1)
Geographical
Region
Total: 20 Total: 56
Europe 2 5.7 (1.3 to 22.5) 0.50 98% 33 29.8 (23.3 to 37.2) 0.02 97%
Asia 7 5.9 (0.2 to 63.8) 7 62.3 (34.9 to 83.6)
Middle East/North
Africa
3 6.8 (0.2 to 72.5) 3 36.5 (10.6 to 73.6)
North America 4 6.5 (0.2 to 69.1) 9 39.2 (18.1 to 65.3)
South America 2 25.1 (0.7 to 93.7) 4 17.1 (4.9 to 45.1)
Oceania 2 10.0 (0.3 to 82.9) - -
Study sample size* Total: 20 Total: 56
median 10 11.2 (6.3 to 19.2) 0.06 97% 29 35.8 (27.1 to 45.7) 0.80 98%
>median 10 5.0 (1.1 to 19.6) 27 32.7 (15.3 to 56.6)
*Median study sample size in general population studies was n = 880 and in clinical obese population studies was n = 77
All average BMIs were over 25 in clinical obese population studies
doi:10.1371/journal.pone.0140908.t002
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populations, spanning levels that are much lower than many claims in commentaries and nar-
rative reviews [1,23] (as low as 2% and 5%, respectively in general and clinical obese popula-
tions) to very high levels which, if true, would represent a potential future major public health
problem (29% and 83% respectively in general and clinically obese populations).
Meta-analysis of available within-study comparisons provided strong evidence that preva-
lence is higher on average in males compared with females and increases incrementally with
greater BMI. However, these associations also varied considerably across studies. Meta-
regression also provided some evidence of differences in prevalence across diagnostic methods
and geographical areas, but residual heterogeneity from all univariable meta-regressions
remained high.
Although we assessed prevalence differences by geographical region of study, we did not
have sufficient information on the distribution of ethnicity in each study to assess whether
NAFLD prevalence differed between ethnic groups. Furthermore, when studies used elevated
ALT to diagnose NAFLD, the thresholds used ranged from 20U/L to 50U/L, with few studies
using sex-specific thresholds. Studies used varying exclusion criteria to identify NAFLD cases,
with many providing little or no information on this, thus, we cannot be certain that some
NAFLD cases are not due to secondary causes of fatty liver, such as alcohol consumption, hepa-
titis or other hepatic diseases such as Wilson’s or hepatotoxic medication, and that varying
exclusion criteria may explain some of the remaining heterogeneity and apparently wide pre-
diction interval for NAFLD. That said, it is unlikely that cases are due to alcohol consumption
given the average age in each of the studies (interquartile range: 11.2 to 15.0 years).
In both the clinical and general population studies, USS was the most common method for
assessing NAFLD, followed by elevated ALT. In general population studies, there was no evi-
dence that NAFLD prevalence differed by diagnostic method. In studies of clinical populations
of obese children/adolescents, pooled prevalence estimates were similar when NAFLD was
diagnosed by USS and MRI; however these estimates were much lower than the prevalence
reported by the one clinical study using liver biopsies. This could suggest that in clinical popu-
lations of obese children/adolescents, USS and MRI underestimate NAFLD prevalence, which
is plausible given the difficulty of accurate scanning in very obese individuals. However, it
should also be noted that the one liver biopsy study in clinically obese young people consisted
entirely of morbidly obese patients, with a mean BMI of 59.1 kg/m2 (range, 42.0–88.1 kg/m2)
which is higher than in the other studies of clinically obese participants. Prevalence estimates
in clinical studies of obese children/adolescents and in obese children/adolescents from the
general population were substantially lower when elevated ALT rather than biopsies, USS or
MRI was used to assess NAFLD. In contrast, in normal weight children/adolescents from the
general population, NAFLD prevalence appeared to be higher when ALT was used compared
to when USS was used to diagnose NAFLD. Thus, elevated ALT may underestimate NAFLD in
obese young people and overestimate it in those who are normal weight.
In both general population studies and clinical studies of obese children/adolescents the
prevalence was consistently higher in males than in females with all methods used to diagnose
NAFLD, with the exception that in general population studies using USS to diagnose NAFLD,
prevalence estimates were similar in males and females. Thus, studies should endeavour to
report prevalence estimates separately for males and females.
Study strengths and limitations
This is the first systematic review and meta-analysis of NAFLD prevalence in children and ado-
lescents and we have systematically searched and included any study that reported a NAFLD
prevalence in a paediatric or adolescent population, irrespective of the aim of the study.
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Although there was considerable heterogeneity between studies which was not adequately
explained by a range of study characteristic, our review provides the best and most comprehen-
sive estimate of NAFLD prevalence in young people in the general population and in clinical
obese populations to date, and importantly, allows the comparison of prevalence between vari-
ous groups of interest. Any systematic review and meta-analysis can only be as good as the
quality of, and information in, the included studies, as well as the extent to which publication
bias might influence results. Systematically searching for and including any study reporting
NAFLD prevalence in a paediatric or adolescent population, irrespective of the aim of the
study, may have reduced the influence of publication bias. However, there may be within-study
publication bias such as not presenting prevalence stratified by gender or BMI categories when
there are no differences (or differences that are in the opposite direction to those expected).
Studies in which the primary aim was to examine some association (the majority of studies)
might be less likely to be published if results were null (or contrary to expected) and if the likeli-
hood of that were related to prevalence that could produce publication bias in this study. Stud-
ies used varying exclusion criteria to identify NAFLD cases and we therefore cannot rule out
that some NAFLD cases are not due to secondary causes of fatty liver. The pooled prevalence
estimates reflect NAFLD-spectrum disease and provides no suggestion of the severity of disease
(i.e. steatosis, fibrosis or NASH). The univariable meta-regression analyses provided weak evi-
dence of ‘small study effects’ in general population studies [30] as prevalence was on average
greater in studies with smaller sample sizes.
We used random-effects meta-regressions which allow for residual heterogeneity not
explained by study-level covariates.[31] However, random-effects meta-regression analyses
have low power, particularly in the presence of large unexplained heterogeneity. Furthermore,
between-study relationships investigated using meta-regression may not represent within-
study relationships, due to the possibility of confounding (or ecological bias). Individual-level
data would facilitate a more detailed examination of the dependence of NAFLD prevalence on
individual-level factors and their interrelationships.
Conclusion
The prevalence of NAFLD is higher in studies of obese clinical populations than in general
population studies. Prevalence is greater in males than females and increases incrementally
with BMI category. Future studies should provide detailed information on exclusion criteria
used to define NAFLD. Having a standard agreed set of exclusion criteria (i.e. other potential
causes of liver fat that need to be ruled out prior to arriving at a diagnosis of NAFLD) and
applying these consistently in research studies and in clinical practice is imperative to under-
standing the true prevalence of NAFLD. Providing prevalence separately in females and males
and by ethnicity may also provide a better understanding of how NAFLD prevalence varies
between different populations. Finally, given that sensitivity and specificity are lower for ALT
than for MRI [15], and that prevalence estimates were similar for USS and MRI, our results
tentatively suggest that ALT may underestimate NAFLD prevalence in young obese people,
and overestimate prevalence in the general population.
Supporting Information
S1 Checklist.
(DOCX)
S1 Dataset.
(DTA)
Prevalence of NAFLD in Children and Adolescents: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0140908 October 29, 2015 12 / 14
S1 File.
(DOCX)
Acknowledgments
We are extremely grateful to authors of published papers who provided us with additional
information. We are also thankful to Jie Zheng, Luisa Zuccolo and Carolina Bonilla from the
School of Social and Community Medicine, University of Bristol, for translating the non-
English publications. The views in this paper and all responsibility for accuracy of data abstrac-
tion and analyses are the authors.
Author Contributions
Conceived and designed the experiments: AF LDH DAL. Performed the experiments: ELA AF
LDH DAL. Analyzed the data: ELA AF HEJ JPTH. Wrote the paper: ELA LDH DAL AF HEJ
JPTH. Had the initial idea for the study: AF LDH DAL. Designed the study and wrote protocols
of identifying studies, extracting data and completing analyses: AF LDH DAL ELA. Identified
studies and abstracted data from all included studies: ELA. Acted as second independent
abstractors, each abstracting from a different subset of studies: AF LDH DAL. Undertook all
statistical analyses with supervision from AF and input from HEJ and JPTH: ELA. Wrote the
first draft of the paper and coordinated comments from other co-authors: ELA. Made critical
comments on earlier drafts and contributed to the writing of the final paper: ELA LDH DAL
AF HEJ JPTH. Acted as guarantors: ELA AF.
References
1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).
Ann Hepatol 2009; 8 Suppl 1:S4–S8. PMID: 19381118
2. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease.
Semin Liver Dis 2008; 28:370–379. doi: 10.1055/s-0028-1091981 PMID: 18956293
3. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature.
Medicine (Baltimore) 1962; 41:249–276.
4. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of Fatty Liver in Chil-
dren and Adolescents. Pediatrics 2006; 118:1388–1393. PMID: 17015527
5. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninva-
sive. Semin Liver Dis 2008; 28:386–395. doi: 10.1055/s-0028-1091983 PMID: 18956295
6. Kim D, KimWR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortal-
ity among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;
57:1357–1365. doi: 10.1002/hep.26156 PMID: 23175136
7. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH
based on the EASL 2009 special conference. J Hepatol 2010; 53:372–384. doi: 10.1016/j.jhep.2010.
04.008 PMID: 20494470
8. Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev
Clin Lab Sci 1980; 12:1–58. PMID: 6104563
9. Lott J, Olf P. Alanine and aspartate aminotransferase (ALT and AST). Clinical enzymology: a case-ori-
ented approach. Chicago: Year Book Medical Publishers, 1986:111–138.
10. Schwimmer JB, DunnW, Norman GJ, Pardee PE, Middleton MS, Kerkar N et al. SAFETY Study: Ala-
nine Aminotransferase Cutoff Values Are Set Too High for Reliable Detection of Pediatric Chronic Liver
Disease. Gastroenterology 2010; 138:1357–1364. doi: 10.1053/j.gastro.2009.12.052 PMID: 20064512
11. Park HN, Sinn DH, Gwak GY, Kim JE, Rhee SY, Eo SJ et al. Upper normal threshold of serum alanine
aminotransferase in identifying individuals at risk for chronic liver disease. Liver Int 2012; 32:937–944.
doi: 10.1111/j.1478-3231.2011.02749.x PMID: 22260521
12. Lockitch G, Halstead AC, Albersheim S, MacCallum C, Quigley G. Age- and sex-specific pediatric refer-
ence intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem
1988; 34:1622–1625. PMID: 3402068
Prevalence of NAFLD in Children and Adolescents: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0140908 October 29, 2015 13 / 14
13. Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF et al. Upper limits of normal for serum alanine amino-
transferase levels in Chinese Han population. PLoS One 2012; 7:e43736. doi: 10.1371/journal.pone.
0043736 PMID: 22962588
14. Prati D, Taioli E, Zanella A, Della TE, Butelli S, Del VE et al. Updated definitions of healthy ranges for
serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1–10. PMID: 12093239
15. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the
relationship of serum aminotransferases to severity of steatosis. Journal of Pediatric Gastroenterology
and Nutrition 2003;2002/12/25:54–61. PMID: 12499997
16. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D et al. The diagnostic value of bio-
markers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10. PMID: 16375767
17. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D et al. The diagnostic value of bio-
markers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10. PMID: 16375767
18. Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C et al. Liver damage in severely
obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg 2004;
14:952–958. PMID: 15329185
19. Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat
quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver
disease. Acta Paediatr 2007; 96:542–547. PMID: 17306008
20. Radetti G, KleonW, Stuefer J, Pittschieler K. Non-alcoholic fatty liver disease in obese children evalu-
ated by magnetic resonance imaging. Acta Paediatr 2006; 95:833–837. PMID: 16801180
21. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and
reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;
54:1082–1090. doi: 10.1002/hep.24452 PMID: 21618575
22. Bohte AE, vanWerven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for
the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011;
21:87–97. doi: 10.1007/s00330-010-1905-5 PMID: 20680289
23. Hesham A-K. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J
Pediatr 2009; 5:245–254. doi: 10.1007/s12519-009-0048-8 PMID: 19911138
24. Angulo P. Obesity and Nonalcoholic Fatty Liver Disease. Nutrition Reviews 2007; 65:S57–S63. PMID:
17605315
25. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N et al. Gender-specific differences
in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepa-
tology 2011; 53:800–809. doi: 10.1002/hep.24097 PMID: 21374659
26. Trikalinos TA, Trow P, Schmid CH. Simulation-Based Comparison of Methods for Meta-Analysis of Pro-
portions and Rates. Methods Research Reports 2013.
27. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Commu-
nity Health 2013; 67:974–978. doi: 10.1136/jech-2013-203104 PMID: 23963506
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ
2003; 327:557–560. PMID: 12958120
29. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342:d549.
doi: 10.1136/bmj.d549 PMID: 21310794
30. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical
tests and prevalence in the literature. J Clin Epidemiol 2000; 53:1119–1129. PMID: 11106885
31. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted?
Statist Med 2002; 21:1559–1573.
Prevalence of NAFLD in Children and Adolescents: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0140908 October 29, 2015 14 / 14
